Skip to main
MGX
MGX logo

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Inc. has demonstrated a robust gene editing approach with sustained FVIII levels at 80% after 19 months in its non-human primate studies, indicating the potential long-term efficacy of its therapies. The company's proprietary metagenomics-derived genome editing toolbox, which includes various systems for both small and large gene edits, positions it well for advancements in genetic medicine. Furthermore, Metagenomi's focus on addressing significant diseases, such as Hemophilia A and cardiovascular disorders, underscores its commitment to developing innovative curative therapeutics that may drive future growth and market confidence.

Bears say

Metagenomi Inc. reported a substantial net loss of $19.9 million, or $0.54 per share, for the second quarter of 2025, indicating ongoing financial challenges. The company's stock is trading significantly below its cash position, which suggests potential upside; however, there are considerable risks that may impede future growth, including delays in advancing pipeline candidates, adverse clinical data outcomes, and potential long-term dilution. These factors contribute to a negative outlook, as the company faces significant hurdles in its pursuit of developing curative therapeutics and establishing a viable commercial presence.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.